Eli Non Current Assets Total from 2010 to 2024

LLY Stock  USD 748.01  1.91  0.25%   
Eli Lilly Non Current Assets Total yearly trend continues to be fairly stable with very little volatility. Non Current Assets Total are likely to outpace its year average in 2024. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
1985-12-31
Previous Quarter
41.7 B
Current Value
44.2 B
Quarterly Volatility
9.5 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli Lilly's main balance sheet or income statement drivers, such as Depreciation And Amortization of 941.5 M, Interest Expense of 510.2 M or Total Revenue of 35.8 B, as well as many indicators such as Price To Sales Ratio of 16.15, Dividend Yield of 0.0074 or PTB Ratio of 51.15. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
  
Check out the analysis of Eli Lilly Correlation against competitors.

Latest Eli Lilly's Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of Eli Lilly and over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Eli Lilly's Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

Eli Non Current Assets Total Regression Statistics

Arithmetic Mean25,386,277,667
Geometric Mean22,287,037,304
Coefficient Of Variation34.65
Mean Deviation5,747,189,511
Median24,998,400,000
Standard Deviation8,795,332,049
Sample Variance77357865.9T
Range38.2B
R-Value0.87
Mean Square Error19717900.7T
R-Squared0.76
Significance0.000021
Slope1,718,260,554
Total Sum of Squares1083010122T

Eli Non Current Assets Total History

202440.2 B
202338.3 B
202231.5 B
202130.4 B
202029.2 B
201925.6 B
201823.4 B

About Eli Lilly Financial Statements

Eli Lilly investors use historical fundamental indicators, such as Eli Lilly's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Assets Total38.3 B40.2 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.